{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:42:33Z","timestamp":1790516553490,"version":"4.1.0"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2019.00898","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T15:01:19Z","timestamp":1566226879000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":68,"title":["Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy"],"prefix":"10.3389","volume":"10","author":[{"given":"Didu S. T.","family":"Kariyawasam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"D'Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique M.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11910-017-0798-y","article-title":"Treatment advances in spinal muscular atrophy","volume":"17","author":"Bharucha-Goebel","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","article-title":"Advances in therapy for spinal muscular atrophy: promises and challenges","volume":"14","author":"Groen","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"B3","first-page":"117","article-title":"Chapter 8 - Spinal muscular atrophies","volume-title":"Neuromuscular Disorders of Infancy, Childhood, and Adolescence.","author":"Darras","year":"2015"},{"key":"B4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s13311-014-0314-x","article-title":"The genetics of spinal muscular atrophy: progress and challenges","volume":"12","author":"Farrar","year":"2015","journal-title":"Neurotherapeutics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightcycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am J Hum Genet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13023-019-1052-2","article-title":"Getting ready for the adult world\u201d: how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being","volume":"14","author":"Wan","year":"2019","journal-title":"Orphanet J Rare Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e020907","DOI":"10.1136\/bmjopen-2017-020907","article-title":"Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives","volume":"8","author":"Farrar","year":"2018","journal-title":"BMJ Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.prrv.2018.03.003","article-title":"New and developing therapies in spinal muscular atrophy","volume":"28","author":"Kariyawasam","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum Mol Genet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/ng854","article-title":"Disruption of an SF2\/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1","volume":"30","author":"Cartegni","year":"2002","journal-title":"Nat Genet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1006\/bbrc.1995.2135","article-title":"Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients","volume":"213","author":"Gennarelli","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1128\/MCB.01262-08","article-title":"Regulation of SMN protein stability","volume":"29","author":"Burnett","year":"2009","journal-title":"Mol Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/ng1207","article-title":"A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy","volume":"34","author":"Kashima","year":"2003","journal-title":"Nat Genet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semcdb.2014.04.026","article-title":"SMN control of RNP assembly: from post-transcriptional gene regulation to motor neuron disease","volume":"32","author":"Li","year":"2014","journal-title":"Semin Cell Dev Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1007\/s00018-018-2849-1","article-title":"The role of survival motor neuron protein (SMN) in protein homeostasis","volume":"75","author":"Chaytow","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e00447","DOI":"10.1002\/prp2.447","article-title":"Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs","volume":"6","author":"Poirier","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.cca.2010.07.035","article-title":"Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) regulates the level of SMN expression through ubiquitination in primary spinal muscular atrophy fibroblasts","volume":"411","author":"Hsu","year":"2010","journal-title":"Clin Chim Acta"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.neuint.2004.04.005","article-title":"Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin\/proteasome pathway","volume":"45","author":"Chang","year":"2004","journal-title":"Neurochem Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1093\/hmg\/ddr288","article-title":"Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice","volume":"20","author":"Kwon","year":"2011","journal-title":"Hum Mol Genet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1172\/JCI71318","article-title":"Dysregulation of ubiquitin homeostasis and \u03b2-catenin signaling promote spinal muscular atrophy","volume":"124","author":"Wishart","year":"2014","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1212\/WNL.92.15_supplement.S25.007","article-title":"Update from SUNFISH part 1: safety, tolerability and PK\/PD from the dose-finding study, including exploratory efficacy data in patients with Type 2 or 3 spinal muscular atrophy (SMA) treated with risdiplam (RG7916) (S25.007)","volume":"92","author":"Mercuri","year":"2019","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1136\/jmedgenet-2018-105482","article-title":"Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol","volume":"56","author":"Tiziano","year":"2019","journal-title":"J Med Genet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0203398","DOI":"10.1371\/journal.pone.0203398","article-title":"Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice","volume":"13","author":"Strathmann","year":"2018","journal-title":"PLoS ONE"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e33572","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"Crawford","year":"2012","journal-title":"PLoS ONE"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0201764","DOI":"10.1371\/journal.pone.0201764","article-title":"A new biomarker candidate for spinal muscular atrophy: identification of a peripheral blood cell population capable of monitoring the level of survival motor neuron protein","volume":"13","author":"Otsuki","year":"2018","journal-title":"PLoS ONE"},{"key":"B30","doi-asserted-by":"publisher","first-page":"a018309","DOI":"10.1101\/cshperspect.a018309","article-title":"Neurofilaments and neurofilament proteins in health and disease","volume":"9","author":"Yuan","year":"2017","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ana.24552","article-title":"Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis","volume":"79","author":"Weydt","year":"2016","journal-title":"Ann Neurol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1177\/1352458512443092","article-title":"Neurofilaments as biomarkers in multiple sclerosis","volume":"18","author":"Teunissen","year":"2012","journal-title":"Mult Scler"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jnnp-2018-320033","article-title":"Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen","author":"Winter","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B34","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann Clin Transl Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1016\/j.nmd.2018.06.310","article-title":"SMA THERAPIES II AND BIOMARKERS: P.262Phosphorylated neurofilament heavy chain (pNF-H) levels in infants and children with SMA: evaluation of pNF-H as a potential biomarker of SMA disease activity","volume":"28","author":"Crawford","year":"2018","journal-title":"Neuromusc Disord"},{"key":"B36","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1016\/j.nmd.2018.06.311","article-title":"SMA THERAPIES II AND BIOMARKERS: P.263Neurofilament light chain as a potential biomarker in spinal muscular atrophy","volume":"28","author":"Jullien de Pommerol","year":"2018","journal-title":"Neuromusc Disord"},{"key":"B37","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/jhg.2015.104","article-title":"Joint effect of the SMN2 and SERF1A genes on childhood-onset types of spinal muscular atrophy in Serbian patients","volume":"60","author":"Brkusanin","year":"2015","journal-title":"J Hum Genet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12891-015-0457-x","article-title":"Molecular characterization and copy number of SMN1, SMN2 and NAIP in Chinese patients with spinal muscular atrophy and unrelated healthy controls","volume":"16","author":"Fang","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"B39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/mgg3.141","article-title":"SMN1 and SMN2 copy numbers in cell lines derived from patients with spinal muscular atrophy as measured by array digital PCR","volume":"3","author":"Stabley","year":"2015","journal-title":"Mol Genet Genomic Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"B41","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/mus.21350","article-title":"An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy","volume":"40","author":"Elsheikh","year":"2009","journal-title":"Muscle Nerve"},{"key":"B42","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1212\/WNL.0000000000006026","article-title":"Precious SMA natural history data","volume":"91","author":"Darras","year":"2018","journal-title":"Neurology."},{"key":"B45","first-page":"805","article-title":"Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy","volume":"57","author":"Cobben","year":"1995","journal-title":"Am J Hum Genet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1086\/515465","article-title":"Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number","volume":"60","author":"McAndrew","year":"1997","journal-title":"Am J Hum Genet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","article-title":"A positive modifier of spinal muscular atrophy in the SMN2 gene","volume":"85","author":"Prior","year":"2009","journal-title":"Am J Hum Genet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1136\/jmg.2010.079004","article-title":"The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor","volume":"47","author":"Bernal","year":"2010","journal-title":"J Med Genet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/hmg\/ddx166","article-title":"A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy","volume":"26","author":"Wu","year":"2017","journal-title":"Hum Mol Genet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00439-019-01983-0","article-title":"Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype","volume":"138","author":"Ruhno","year":"2019","journal-title":"Hum Genet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1745-7254.2005.00145.x","article-title":"Plastins: versatile modulators of actin organization in (patho)physiological cellular processes","volume":"26","author":"Delanote","year":"2005","journal-title":"Acta Pharmacol Sinica"},{"key":"B52","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/jhg.2013.111","article-title":"Correlation of PLS3 expression with disease severity in children with spinal muscular atrophy","volume":"59","author":"Yanyan","year":"2014","journal-title":"J Hum Genet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1001\/archneurol.2010.239","article-title":"Association of plastin 3 expression with disease severity in spinal muscular atrophy only in postpubertal females","volume":"67","author":"Stratigopoulos","year":"2010","journal-title":"Arch Neurol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/hmg\/dds540","article-title":"Plastin 3 ameliorates spinal muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality","volume":"22","author":"Ackermann","year":"2013","journal-title":"Hum Mol Genet"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e0132364","DOI":"10.1371\/journal.pone.0132364","article-title":"Plastin 3 expression does not modify spinal muscular atrophy severity in the \u03947 SMA mouse","volume":"10","author":"McGovern","year":"2015","journal-title":"PLoS ONE"},{"key":"B56","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ajhg.2016.07.014","article-title":"The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype","volume":"99","author":"Hosseinibarkooie","year":"2016","journal-title":"Am J Hum Genet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","article-title":"Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis","volume":"100","author":"Riessland","year":"2017","journal-title":"Am J Hum Genet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1038\/mtna.2016.47","article-title":"Altered levels of microRNA-9,\u2212206, and\u2212132 in spinal muscular atrophy and their response to antisense oligonucleotide therapy","volume":"5","author":"Catapano","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"B59","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1631\/jzus.B1500072","article-title":"Association between SMN2 methylation and disease severity in Chinese children with spinal muscular atrophy","volume":"17","author":"Cao","year":"2016","journal-title":"J Zhejiang Univ Sci B"},{"key":"B60","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/hmg\/ddn357","article-title":"Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition","volume":"18","author":"Hauke","year":"2009","journal-title":"Hum Mol Genet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/ejhg.2012.293","article-title":"Genome-wide analysis shows association of epigenetic changes in regulators of Rab and Rho GTPases with spinal muscular atrophy severity","volume":"21","author":"Zheleznyakova","year":"2013","journal-title":"Eur J Hum Genet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ahg.12288","article-title":"DYNC1H1 gene methylation correlates with severity of spinal muscular atrophy","volume":"83","author":"Maretina","year":"2019","journal-title":"Ann Hum Genet"},{"key":"B63","doi-asserted-by":"publisher","first-page":"20427","DOI":"10.3390\/ijms141020427","article-title":"An emerging role for long non-coding RNA dysregulation in neurological disorders","volume":"14","author":"Fenoglio","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1006\/geno.2001.6543","article-title":"The Prader-Willi syndrome imprinting center activates the paternally expressed murine Ube3a antisense transcript but represses paternal Ube3a","volume":"73","author":"Chamberlain","year":"2001","journal-title":"Genomics"},{"key":"B65","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nm1784","article-title":"Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase","volume":"14","author":"Faghihi","year":"2008","journal-title":"Nat Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nature13975","article-title":"Towards a therapy for Angelman syndrome by targeting a long non-coding RNA","volume":"518","author":"Meng","year":"2015","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neuron.2016.11.033","article-title":"The antisense transcript SMN-AS1 regulates SMN expression and is a novel therapeutic target for spinal muscular atrophy","volume":"93","author":"D'Ydewalle","year":"2017","journal-title":"Neuron"},{"key":"B68","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13311-016-0473-z","article-title":"Assessment of motor units in neuromuscular disease","volume":"14","author":"Henderson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B69","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1152\/physiol.00040.2015","article-title":"Principles of motor unit physiology evolve with advances in technology","volume":"31","author":"Farina","year":"2016","journal-title":"Physiology"},{"key":"B70","first-page":"241","article-title":"Peripheral nerve conduction studies and neuromuscular junction testing","volume-title":"Handbook of Clinical Neurophysiology.","author":"Kimura","year":"2004"},{"key":"B71","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/acn3.23","article-title":"Electrophysiological biomarkers in spinal muscular atrophy: preclinical proof of concept","volume":"1","author":"Arnold","year":"2014","journal-title":"Ann Clin Transl Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"ii32","DOI":"10.1136\/jnnp.2005.069211","article-title":"The basics of electromyography","volume":"76","author":"Mills","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B73","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/mus.23967","article-title":"The motor neuron response to SMN1 deficiency in spinal muscular atrophy","volume":"49","author":"Kang","year":"2014","journal-title":"Muscle Nerve"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/j.ejpn.2017.04.1218","article-title":"Efficacy and safety of nusinersen in infants with presymptomatic spinal muscular atrophy (SMA): interim results from the NURTURE study","volume":"21","author":"Bertini","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/mus.21838","article-title":"Compound muscle action potential and motor function in children with spinal muscular atrophy","volume":"42","author":"Lewelt","year":"2010","journal-title":"Muscle Nerve"},{"key":"B76","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/acn3.283","article-title":"Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study","volume":"3","author":"Kolb","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1093\/brain\/awr229","article-title":"Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy","volume":"134","author":"Farrar","year":"2011","journal-title":"Brain"},{"key":"B78","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e52899","DOI":"10.3791\/52899","article-title":"Electrophysiological motor unit number estimation (MUNE) measuring compound muscle action potential (CMAP) in mouse hindlimb muscles","author":"Arnold","year":"2015","journal-title":"J Vis Exp"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e111428","DOI":"10.1371\/journal.pone.0111428","article-title":"A comparison of three electrophysiological methods for the assessment of disease status in a mild spinal muscular atrophy mouse model","volume":"9","author":"Li","year":"2014","journal-title":"PLoS ONE."},{"key":"B82","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/146608202317576516","article-title":"Changes in motor unit numbers in patients with ALS: a longitudinal study using the adapted multiple point stimulation method","volume":"3","author":"Wang","year":"2002","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/mus.1128","article-title":"Depletion and sizes of motor units in spinal muscular atrophy","volume":"24","author":"Galea","year":"2001","journal-title":"Muscle Nerve"},{"key":"B84","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/mus.10050","article-title":"Motor unit number estimation in infants and children with spinal muscular atrophy","volume":"25","author":"Bromberg","year":"2002","journal-title":"Muscle Nerve"},{"key":"B85","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.nmd.2014.11.012","article-title":"Motor unit loss estimation by the multipoint incremental MUNE method in children with spinal muscular atrophy\u2013a preliminary study","volume":"25","author":"Gawel","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"B86","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S1567-424X(09)70145-X","article-title":"Motor unit number estimation (MUNE) with nerve conduction studies","volume":"53","author":"Daube","year":"2000","journal-title":"Suppl Clin Neurophysiol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jns.2005.11.011","article-title":"Motor unit number estimates\u2013from A to Z","volume":"242","author":"Daube","year":"2006","journal-title":"J Neurol Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ana.24332","article-title":"A large animal model of spinal muscular atrophy and correction of phenotype","volume":"77","author":"Duque","year":"2015","journal-title":"Ann Neurol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.expneurol.2003.07.008","article-title":"Counting motor units in chronic motor neuropathies","volume":"184","author":"Bromberg","year":"2003","journal-title":"Exp Neurol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/mus.24318","article-title":"The motor neuron response to SMN1 deficiency in spinal muscular atrophy","volume":"50","author":"Arnold","year":"2014","journal-title":"Muscle Nerve."},{"key":"B91","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/mus.24442","article-title":"Motor unit number estimation: a technology and literature review","volume":"50","author":"Gooch","year":"2014","journal-title":"Muscle Nerve"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1152\/japplphysiol.00910.2017","article-title":"Improved motor unit number estimate when motor unit alternation is addressed","volume":"125","author":"DeForest","year":"2018","journal-title":"J Appl Physiol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/ana.410280404","article-title":"Methods for estimating the number of motor units in human muscles","volume":"28","author":"Stein","year":"1990","journal-title":"Ann Neurol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.clinph.2018.11.009","article-title":"Motor Unit Number Index (MUNIX) of hand muscles is a disease biomarker for adult spinal muscular atrophy","volume":"130","author":"Gunther","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3791\/56805","article-title":"CMAP scan MUNE (MScan) - a novel motor unit number estimation (MUNE) method","author":"Jacobsen","year":"2018","journal-title":"J Vis Exp"},{"key":"B96","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/mus.10048","article-title":"Localized bioimpedance analysis in the evaluation of neuromuscular disease","volume":"25","author":"Rutkove","year":"2002","journal-title":"Muscle Nerve"},{"key":"B97","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/WCO.0000000000000593","article-title":"Neurophysiological biomarkers in amyotrophic lateral sclerosis","volume":"31","author":"Vucic","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"a034405","DOI":"10.1101\/cshperspect.a034405","article-title":"Electrical impedance methods in neuromuscular assessment: an overview","volume":"8","author":"Rutkove","year":"2018","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/j.clinph.2007.08.004","article-title":"Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials","volume":"118","author":"Rutkove","year":"2007","journal-title":"Clin Neurophysiol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/21678421.2018.1510008","article-title":"Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system","volume":"19","author":"Shefner","year":"2018","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."},{"key":"B101","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/mus.23233","article-title":"Electrical impedance myography in spinal muscular atrophy: a longitudinal study","volume":"45","author":"Rutkove","year":"2012","journal-title":"Muscle Nerve"},{"key":"B102","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/mus.25385","article-title":"Muscle magnetic resonance imaging in spinal muscular atrophy type 3: selective and progressive involvement","volume":"55","author":"Durmus","year":"2017","journal-title":"Muscle Nerve"},{"key":"B103","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S1474-4422(15)00320-8","article-title":"MRI quantifies neuromuscular disease progression","volume":"15","author":"Forbes","year":"2016","journal-title":"Lancet Neurol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1136\/jnnp.2009.200519","article-title":"Muscle ultrasonography to predict survival in amyotrophic lateral sclerosis","volume":"82","author":"Arts","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B105","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/mus.25066","article-title":"Quantifying disease progression in amyotrophic lateral sclerosis using peripheral nerve sonography","volume":"54","author":"Schreiber","year":"2016","journal-title":"Muscle Nerve"},{"key":"B106","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.clinph.2014.08.002","article-title":"Ultrasound in ALS: is it a sound method?","volume":"126","author":"De Carvalho","year":"2015","journal-title":"Clin Neurophysiol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.nmd.2011.09.007","article-title":"A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology","volume":"22","author":"Bowerman","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1212\/WNL.0b013e3182749eca","article-title":"Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3","volume":"79","author":"Wadman","year":"2012","journal-title":"Neurology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/labinvest.3700163","article-title":"Reduced expression of nicotinic AChRs in myotubes from spinal muscular atrophy I patients","volume":"84","author":"Arnold","year":"2004","journal-title":"Lab Invest"},{"key":"B110","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.nmd.2017.07.007","article-title":"6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction","volume":"27","author":"Pera","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"B111","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","article-title":"Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy","volume":"74","author":"Montes","year":"2010","journal-title":"Neurology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JND-180342","article-title":"Perceived fatigue in spinal muscular atrophy: a pilot study","volume":"6","author":"Dunaway Young","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"B113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-7506-7332-7.50006-4","article-title":"Chapter 2 - Neurologic evaluation and ancillary tests","volume-title":"Neuromuscular Case Studies.","author":"Bertorini","year":"2008"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e019932","DOI":"10.1136\/bmjopen-2017-019932","article-title":"Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)","volume":"8","author":"Stam","year":"2018","journal-title":"BMJ Open"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.00898\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T05:24:08Z","timestamp":1721625848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.00898\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":114,"alternative-id":["10.3389\/fneur.2019.00898"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2019.00898","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"article-number":"898"}}